

Jelmyto® (mitomycin) (Intra-pyelocalyceal)



Document Number: IC-0586

Date Approved: 03/04/2025

Date of Origin: 02/02/2021

Dates Reviewed: 02/2021, 06/2021, 06/2022, 06/2023, 06/2024, 01/2025

I. Length of Authorization

Coverage will be provided initially for 3 months and may be renewed one time only for 11 months (*maximum total of 17 doses from initial and maintenance treatments*).

II. Dosing Limits

Max Units (per dose and over time) [HCPCS Unit]:

- Initial: 80 billable units per week for 6 weeks
- Maintenance: 80 billable units per month for 11 months

III. Initial Approval Criteria ¹

Coverage is provided in the following conditions:

- Patient is at least 18 years of age; **AND**

Universal Criteria ¹

- Patient does not have a perforation of the bladder or upper urinary tract; **AND**
- Therapy will be used for pyelocalyceal instillation only; **AND**
- Used as a single agent; **AND**

Urothelial Carcinoma † ‡ ◊ ^{1-3,5}

- Patient has low-grade upper tract urothelial cancer (LG-UTUC); **AND**
- Used as primary treatment; **AND**
- Patient has at least one measurable tumor 5 to ≤ 15 mm; **AND**
- Patient has not received intravesical BCG treatment within the previous 6 months of starting therapy

Preferred therapies and recommendations are determined by review of clinical evidence. NCCN category of recommendation is taken into account as a component of this review. Regimens deemed equally efficacious (i.e., those having the same NCCN categorization) are considered to be therapeutically equivalent.

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Ⓢ Orphan Drug

IV. Renewal Criteria ¹

Coverage may be renewed based upon the following criteria:

- Patient continues to meet the universal and indication specific criteria as identified in section III; **AND**
- Duration of authorization has not been exceeded (*refer to Section I*); **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Patient has a complete response (CR) to initial therapy (consisting of 3 months of therapy) defined as a negative ureteroscopic evaluation and negative urine cytology (required for extending treatment for an additional 11 monthly instillations); **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: severe ureteric obstruction, (including ureteral stenosis and hydronephrosis), bone marrow suppression (i.e., severe thrombocytopenia and/or neutropenia), etc.

V. Dosage/Administration ¹

Indication	Dose
Upper Tract Urothelial Carcinoma	<ul style="list-style-type: none"> • The dose to be instilled is 4 mg/mL via ureteral catheter or a nephrostomy tube, with total instillation volume based on volumetric measurements using pyelography, not to exceed 15 mL (60 mg of mitomycin). • Instill Jelmyto once weekly for six weeks. For patients with a complete response 3 months after therapy initiation, instillations may be administered once a month for a maximum of 11 additional instillations.

VI. Billing Code/Availability Information

HCPCS Code:

- J9281 – Mitomycin pyelocalyceal instillation, 1 mg; 1 billable unit = 1 mg

NDC(s):

- Jelmyto single-dose kit: 72493-0103-xx
 - Two 40 mg (each) single-dose vials of lyophilized mitomycin: 72493-0101-xx
 - One 20 mL single dose vial of vehicle for reconstitution: 72493-0102-xx

VII. References (STANDARD)

1. Jelmyto [package insert]. Princeton, NJ; Urogen Pharm, Inc; October 2024. Accessed January 2025.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for mitomycin. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed January 2025.
3. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Bladder Cancer. Version 6.2024. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed January 2025.
4. Kleinmann N, Pierorazio P, Matin S, et al. LBA25 Non-Surgical Management Of Low Grade Upper Tract Urothelial Cancer: An Interim Analysis Of The International Multicenter Olympus Trial (NCT02793128). J Uro 2018.199:45;e1166. <https://doi.org/10.1016/j.juro.2018.03.097>
5. Kleinmann N, Matin SF, Pierorazio PM, et al. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. 2020 Jun;21(6):776-785.

VIII. References (ENHANCED)

- 1e. Prime Therapeutics Management. Jelmyto Clinical Literature Review Analysis. Last updated January 2025. Accessed January 2025.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C65.1	Malignant neoplasm of right renal pelvis
C65.2	Malignant neoplasm of left renal pelvis
C65.9	Malignant neoplasm of unspecified renal pelvis

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologics. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify

benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC